Free Trial
NASDAQ:TRAW

Traws Pharma (TRAW) Stock Price, News & Analysis

Traws Pharma logo
$1.26 +0.06 (+5.00%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.28 +0.02 (+1.59%)
As of 08:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Traws Pharma Stock (NASDAQ:TRAW)

Key Stats

Today's Range
$1.17
$1.28
50-Day Range
$1.10
$2.88
52-Week Range
$0.97
$19.44
Volume
49,962 shs
Average Volume
172,119 shs
Market Capitalization
$7.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Traws Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

TRAW MarketRank™: 

Traws Pharma scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Traws Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Traws Pharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Traws Pharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Traws Pharma has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.88% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 3.77%, indicating that investor sentiment is improving.
  • Dividend Yield

    Traws Pharma does not currently pay a dividend.

  • Dividend Growth

    Traws Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.88% of the float of Traws Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Traws Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Traws Pharma has recently decreased by 3.77%, indicating that investor sentiment is improving.
  • News Sentiment

    Traws Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Traws Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Traws Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.95% of the stock of Traws Pharma is held by institutions.

  • Read more about Traws Pharma's insider trading history.
Receive TRAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter.

TRAW Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Traws Pharma reports FY24 EPS ($35.21)
See More Headlines

TRAW Stock Analysis - Frequently Asked Questions

Traws Pharma's stock was trading at $8.88 at the beginning of the year. Since then, TRAW stock has decreased by 85.8% and is now trading at $1.26.
View the best growth stocks for 2025 here
.

Traws Pharma, Inc. (NASDAQ:TRAW) posted its quarterly earnings results on Thursday, May, 15th. The company reported $2.09 earnings per share for the quarter, beating analysts' consensus estimates of ($8.04) by $10.13. The business earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million.

Traws Pharma's top institutional investors include Adage Capital Partners GP L.L.C. (6.19%), Vestal Point Capital LP (3.28%) and Alyeska Investment Group L.P. (0.99%).

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Nikola (NKLA), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX).

Company Calendar

Last Earnings
5/15/2025
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRAW
Previous Symbol
NASDAQ:TRAW
Employees
17
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,950,000.00
Net Margins
-62,294.25%
Pretax Margin
-62,294.25%

Debt

Sales & Book Value

Annual Sales
$227,000.00
Price / Cash Flow
N/A
Book Value
$12.70 per share
Price / Book
0.10

Miscellaneous

Free Float
3,154,000
Market Cap
$7.01 million
Optionable
Optionable
Beta
1.59
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TRAW) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners